Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 8/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14574006 | 0.87 | PPARG (0.71) | PPARGHTTMAPTPPARACYP2C9 | |
| SCHEMBL670922 | 0.87 | PPARG (0.73) | PPARGPPARACYP2C9EGFRCHRM4 | |
| SCHEMBL13384261 | 0.86 | PPARG (0.79) | PPARGPPARACYP2C9EGFRCHRM4 | |
| SCHEMBL5119415 | 0.86 | PPARG (0.79) | PPARGPPARACYP2C9EGFRCHRM4 | |
| SCHEMBL2896771 | 0.86 | PPARG (0.79) | PPARGPPARACYP2C9EGFRCHRM4 | |
| SCHEMBL2901993 | 0.84 | PPARG (0.69) | PPARGPPARACYP2C9EGFRCHRM4 | |
| SCHEMBL14447483 | 0.84 | PPARG (0.87) | PPARGPPARACYP2C9EGFRCHRM4 | |
| SCHEMBL5126400 | 0.84 | PPARG (0.76) | PPARGPPARACYP2C9EGFRCHRM4 | |
| Mk-0533 SCHEMBL671319 | 0.84 | PPARG (1.00) | PPARGPPARACYP2C9EGFRCHRM4 | |
| Mk-0533 SCHEMBL13384215 | 0.84 | PPARG (1.00) | PPARGPPARACYP2C9EGFRCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537078-B1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7683092-B2 | Crystalline forms of antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683092-B2 | Crystalline forms of antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | MERCK SHARP & DOHME CORP. | 2008-09-11 | — | — | US | disclosed |
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | MERCK SHARP & DOHME CORP. | 2008-09-11 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050277685-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2005-12-15 | — | — | US | disclosed |
| EP-1537078-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | Merck & Co., Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020409-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004020408-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | FFAR2, PPARG, PPARA | PPARG 2/4885HPGD 1538/4885HTT 2391/4885 |
| US-20050277685-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | PPARG 3/4885HPGD 1185/4885HTT 682/4885 |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | PPARD, PPARG, PPARA | PPARG 2/4885HPGD 393/4885HTT 1334/4885 |
| US-20070161689-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | PPARG 3/4885HPGD 1185/4885HTT 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.